Overweight
📧 Sign up to get email alerts when something new happens for Overweight.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-28EMA Authorised: Mounjaro (tirzepatide) — Eli Lilly Nederland B.V.
The EMA authorizes Mounjaro (tirzepatide) for therapeutic use in type 2 diabetes, obesity, and overweight conditions.
-
EMA approval · 2026-08-26EMA Authorised: Wegovy (semaglutide) — Novo Nordisk A/S
EMA authorises Wegovy (semaglutide) by Novo Nordisk A/S for obesity and overweight.
-
EMA approval · 2026-08-25EMA Authorised: Ablymico (liraglutide) — STADA Arzneimittel AG
Ablymico (liraglutide) has been authorised by EMA for obesity and overweight indications.
-
EMA approval · 2026-08-18EMA Authorised: Mounjaro (tirzepatide) — Eli Lilly Nederland B.V.
EMA authorised Mounjaro (tirzepatide) for therapeutic use in type 2 diabetes mellitus, obesity, and overweight conditions.
-
EMA approval · 2026-04-10EMA Authorised: Mysimba (bupropion hydrochloride;naltrexone hydrochloride) — Orexigen Therapeutics Ireland Limited
The EMA authorised Mysimba, a fixed-dose combination of bupropion hydrochloride and naltrexone hydrochloride, for obesity and overweight. Or…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-30EMA Authorised: Wegovy (semaglutide) — Novo Nordisk A/S
The European Medicines Agency authorised Wegovy (semaglutide) from Novo Nordisk A/S for obesity and overweight.
-
FDA approval · 2026-02-25FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
The FDA approved Novo Nordisk's supplemental application for Wegovy (semaglutide), updating the approval to support its chronic weight-manag…
-
FDA approval · 2026-02-25FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Wegovy (semaglutide) from Novo Nordisk. The approval pertains to changes to the product labeling…
-
FDA approval · 2026-01-20FDA Approved: ZEPBOUND — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for ZEPBOUND (tirzepatide) submitted by Eli Lilly and Company.
-
FDA approval · 2025-11-05FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)
FDA approved a supplemental application for CONTRAVE EXTENDED-RELEASE (naltrexone hydrochloride and bupropion hydrochloride) by Nalpropion P…
-
EMA approval · 2025-07-31EMA Authorised: Saxenda (liraglutide) — Novo Nordisk A/S
EMA authorised Saxenda (liraglutide) for obesity and overweight, with Novo Nordisk A/S as the marketing authorization holder.
-
FDA approval · 2024-11-01FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Wegovy (semaglutide) from Novo Nordisk, supporting updated labeling or an expanded indication.
-
FDA approval · 2022-08-24FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
The FDA approved Novo Nordisk's supplemental application for Wegovy (semaglutide). This action expands its labeling to support chronic weigh…
-
FDA approval · 2017-05-04FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)
FDA approved a supplemental application to add CONTRAVE EXTENDED-RELEASE (naltrexone hydrochloride and bupropion hydrochloride) from Nalprop…
-
FDA approval · 2017-01-27FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)
The FDA approved a supplemental application for CONTRAVE EXTENDED-RELEASE (naltrexone hydrochloride and bupropion hydrochloride) from Nalpro…
-
EMA approval · 2015-01-23Saxenda recommended for approval in weight management in adults
The EMA recommended granting approval for Saxenda for weight management in adults, marking its potential entry as a treatment option for obe…
-
FDA approval ·FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
FDA approves a higher-dose 7.2 mg Wegovy (semaglutide) injection for weight loss and maintenance in certain adults under the National Priori…